Sensitive Genotyping of Somatic Mutations in the EGFR, KRAS, PIK3CA, BRAF Genes from NSCLC Patients Using Hydrogel Biochips. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Emelyanova, Marina; Arkhipova, Ksenia; Mazurenko, Natalia; Chudinov, Alexander; Demidova, Irina; Zborovskaya, Irina; Lyubchenko, Lyudmila; Zasedatelev, Alexander; Nasedkina, Tatiana
• Is Part Of: Applied immunohistochemistry & molecular morphology. Volume 23:Issue 4(2015)
• Publication Date: 2015-04
• Subjects: Diagnostic immunohistochemistry -- Periodicals; Immunohistochemistry -- Periodicals; Cells -- Morphology -- Periodicals; Molecular diagnosis -- Periodicals; 616.079
• DOI: 10.1097/PAI.0000000000000084
• Languages: English
• ISSNs: 1541-2016

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Targeted inhibitors of the epidermal growth factor receptor (EGFR) are used for the treatment of non–small cell lung cancer (NSCLC). Somatic mutations in the <italic>EGFR</italic> gene and key effectors of the EGFR-signaling pathway (<italic>KRAS</italic>, <italic>BRAF</italic>, <italic>PIK3CA</italic>) are associated with sensitivity to these drugs. We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common <italic>EGFR</italic>, <italic>KRAS</italic>, <italic>PIK3CA</italic>, and <italic>BRAF</italic> gene mutations. The locked nucleic acid clamp PCR technique was used to increase the sensitivity of the assay, then allele-specific hybridization of a fluorescently labeled target on a biochip was performed. To prove the feasibility of the approach, clinical samples from 112 patients with NSCLC were analyzed. A total of 14 <italic>EGFR</italic> (12.5%) mutations, 21 (18.8%) <italic>KRAS</italic> mutations, 12 (10.7%) <italic>PIK3CA</italic> mutations, and 1 <italic>BRAF</italic> mutation (0.9%) were found. We compared the results with those from direct sequencing. We detected 50 different mutations by the LC-biochip assay and only 33 of them were found by direct sequencing. To demonstrate that the LC-biochip assay did not give false-positive results, the 17 specimens with discordant results were subjected to locked nucleic acid clamp PCR followed by sequencing. The results of this analysis were identical to the results obtained by the LC-biochip assay indicating that the biochip-based assay was both accurate and reliable. This approach was able to detect approximately 0.5% of mutated alleles in wild-type DNA background. The biochip-based assay is a reliable and inexpensive method for the identification of NSCLC patients, who may respond to a specific targeted therapy.</p> </sec> </abstract>